The rising use of GLP-1 receptor agonists (GLP-1 RAs)—medications initially developed for type 2 diabetes—has expanded rapidly, largely driven by their effectiveness in weight management. But as more cancer patients explore these drugs for weight loss or to mitigate treatment side effects, oncologists and oncology pharmacists are carefully evaluating their potential benefits and risks within the complex landscape of cancer care. Understanding how these medications interact with cancer treatment, nutritional status, and overall patient well-being is becoming increasingly crucial.
While GLP-1 RAs like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza) have demonstrated significant success in promoting weight loss and improving metabolic health in the general population, their application in oncology is still evolving. The concern isn’t necessarily that these drugs *cause* cancer, but rather how they might influence the efficacy of cancer treatments, particularly chemotherapy and radiation, and how they affect patients already vulnerable to malnutrition and weight loss—common and debilitating side effects of cancer therapy.
The Challenge of Weight Loss During Cancer Treatment
Unintentional weight loss, known as cancer cachexia, affects a substantial proportion of individuals with cancer—estimates range from 30% to 80%—and is associated with poorer treatment outcomes and reduced quality of life. Traditional approaches to managing weight loss during cancer treatment often involve nutritional support, appetite stimulants, and exercise programs. However, these interventions aren’t always effective, especially during periods of intense treatment like concurrent chemoradiation.
“But during that concurrent chemoradiation phase, the nutritional deficiencies, the extreme weight loss… it’s a really tough situation,” explains oncology pharmacist Sarah Miller, PharmD, BCOP, at the University of North Carolina Medical Center, in a recent presentation. “We’re seeing patients who are already struggling with nausea, vomiting, mucositis, and loss of appetite. Adding a medication that can further suppress appetite or cause gastrointestinal side effects needs to be carefully considered.”
How GLP-1 RAs Might Interact with Cancer Care
The primary mechanism of GLP-1 RAs involves mimicking the effects of the naturally occurring incretin hormone GLP-1, which stimulates insulin release, suppresses glucagon secretion, slows gastric emptying, and promotes a feeling of fullness. While these effects can be beneficial for weight loss, they also raise concerns in the context of cancer treatment.
One key area of investigation is the potential impact on chemotherapy delivery. Some chemotherapeutic agents rely on adequate nutrient absorption for optimal efficacy. The slowed gastric emptying caused by GLP-1 RAs could theoretically reduce the absorption of these drugs, potentially diminishing their effectiveness. However, research in this area is still limited and often conflicting.
GLP-1 RAs can cause gastrointestinal side effects like nausea, vomiting, and diarrhea, which can exacerbate the side effects of chemotherapy and radiation, leading to dehydration and further nutritional decline. Oncology pharmacists are emphasizing the importance of proactive management of these side effects, including careful dose titration, antiemetic medications, and close monitoring of electrolyte levels.
The Role of the Oncology Pharmacist
Oncology pharmacists are playing a pivotal role in navigating the complexities of GLP-1 RA use in cancer patients. They are involved in medication reconciliation, identifying potential drug interactions, and providing education to both patients and healthcare providers.
“We’re really focusing on a patient-specific approach,” says Miller. “We demand to understand the patient’s cancer type, treatment plan, nutritional status, and overall health before even considering whether a GLP-1 RA is appropriate. If a patient is already malnourished or at high risk of malnutrition, we need to be very cautious.”
Pharmacists are also advocating for standardized protocols and guidelines for the use of GLP-1 RAs in oncology. Currently, there is a lack of consensus on optimal dosing, monitoring parameters, and duration of therapy. Ongoing clinical trials are needed to address these knowledge gaps and provide evidence-based recommendations.
Current Research and Ongoing Trials
Several clinical trials are currently underway to investigate the effects of GLP-1 RAs in cancer patients. These studies are exploring various endpoints, including treatment response, quality of life, and survival. For example, researchers are investigating whether GLP-1 RAs can enhance the efficacy of immunotherapy in certain types of cancer. Early results from some studies have been promising, but more data are needed to confirm these findings.
One area of particular interest is the potential for GLP-1 RAs to modulate the tumor microenvironment. Some preclinical studies suggest that these drugs may have anti-angiogenic and anti-inflammatory effects, which could potentially inhibit tumor growth. However, these effects have not yet been consistently demonstrated in humans.
Practical Considerations for Patients and Providers
For cancer patients considering GLP-1 RAs, open communication with their healthcare team is essential. Patients should discuss their medical history, current medications, and any concerns they may have. Healthcare providers should carefully assess the potential risks and benefits of GLP-1 RAs in the context of the individual patient’s cancer and treatment plan.
Key considerations include:
- Nutritional Status: Assess for existing malnutrition or risk of malnutrition.
- Treatment Plan: Consider the potential for drug interactions and impact on chemotherapy absorption.
- Gastrointestinal Tolerance: Monitor for and manage side effects like nausea, vomiting, and diarrhea.
- Hydration: Ensure adequate fluid intake to prevent dehydration.
The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) are expected to release updated guidelines on the use of GLP-1 RAs in oncology in the coming years, providing more specific recommendations for clinical practice. Patients can find more information about cancer-related nutrition and support services through the American Cancer Society and the National Comprehensive Cancer Network.
As research continues to unfold, the role of GLP-1 RAs in cancer care will become clearer. For now, a cautious and individualized approach, guided by the expertise of oncology pharmacists and other healthcare professionals, is paramount. The next major checkpoint will be the release of preliminary data from several ongoing Phase II clinical trials evaluating GLP-1 RA use in combination with standard cancer therapies, expected in late 2024.
Have you or a loved one considered using GLP-1 RAs during cancer treatment? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might find this information helpful.
